The study was of a randomized, double-blinded, crossover, and sham-controlled design.
Twenty patients received 2 weeks\' treatment administered using a nasal spray-device. The subjects were monitored with regard to symptoms (SNOT-22 questionnaire, i.e., the primary efficacy variable), changes to their microbiome, and inflammatory products (IL-6, IL-8, TNF-, IL-8,a, and MPO) in nasal lavage fluids.
Neither symptom scores, microbiological explorations, nor levels of inflammatory products in nasal lavage fluids were affected by LAB (c.f. sham).
Two weeks\' nasal administration of a honeybee LAB microbiome to patients with CRSsNP is well tolerated but affects neither symptom severity nor the microbiological flora/local inflammatory activity.
1b.
这项研究是随机的,双盲,交叉,和假控制设计。
20名患者接受了2周的使用鼻喷雾装置的治疗。对受试者的症状进行了监测(SNOT-22问卷,即,主要功效变量),微生物组的变化,和炎症产物(IL-6,IL-8,TNF-,IL-8,a,和MPO)在鼻灌洗液中。
两个症状评分,微生物勘探,鼻灌洗液中炎症产物的水平也不受LAB(c.f.sham)的影响。
对CRSsNP患者鼻腔给予蜜蜂LAB微生物组两周的耐受性良好,但既不影响症状严重程度,也不影响微生物区系/局部炎症活动。
1b。